Scarica l'app Stockscreener
4.75
2.66%
-0.13
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CARA Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$4.88
Aprire:
$4.73
Volume 24 ore:
45,455
Relative Volume:
0.35
Capitalizzazione di mercato:
$21.71M
Reddito:
$20.97M
Utile/perdita netta:
$-118.51M
Rapporto P/E:
-2.1689
EPS:
-2.19
Flusso di cassa netto:
$-94.45M
1 W Prestazione:
-11.38%
1M Prestazione:
+35.56%
6M Prestazione:
+38.69%
1 anno Prestazione:
-39.31%
Intervallo 1D:
$4.5401
$4.92
Intervallo di 1 settimana:
$4.5401
$5.5232
Portata 52W:
$2.7084
$13.80
Cara Therapeutics Inc Stock (CARA) Company Profile
Nome
Cara Therapeutics Inc
Settore
Industria
Telefono
203-406-3700
Indirizzo
400 ATLANTIC STREET, SUITE 500, STAMFORD, CT
Confronta CARA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CARA
Cara Therapeutics Inc
|
4.75 | 21.71M | 20.97M | -118.51M | -94.45M | -2.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.11 | 106.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.59 | 80.61B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
649.26 | 38.82B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.55 | 31.03B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.15 | 29.28B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cara Therapeutics Inc Stock (CARA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-06-13 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2024-06-13 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-06-13 | Downgrade | Needham | Buy → Hold |
| 2024-06-13 | Downgrade | Stifel | Buy → Hold |
| 2023-03-08 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-03-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-11-01 | Ripresa | Canaccord Genuity | Buy |
| 2021-08-03 | Iniziato | JP Morgan | Neutral |
| 2020-04-21 | Reiterato | H.C. Wainwright | Buy |
| 2019-08-12 | Reiterato | H.C. Wainwright | Buy |
| 2019-05-29 | Reiterato | Laidlaw | Buy |
| 2019-02-06 | Ripresa | Jefferies | Buy |
| 2019-01-15 | Iniziato | BofA/Merrill | Neutral |
| 2018-09-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-13 | Iniziato | Jefferies | Buy |
| 2018-08-08 | Reiterato | Stifel | Buy |
| 2018-06-28 | Reiterato | H.C. Wainwright | Buy |
| 2018-03-12 | Ripresa | H.C. Wainwright | Buy |
| 2018-02-12 | Aggiornamento | Janney | Neutral → Buy |
| 2018-01-19 | Iniziato | Seaport Global Securities | Buy |
| 2017-06-30 | Downgrade | Janney | Buy → Neutral |
| 2017-06-30 | Reiterato | Laidlaw | Buy |
| 2017-06-30 | Reiterato | Stifel | Buy |
| 2017-03-28 | Reiterato | H.C. Wainwright | Buy |
| 2017-03-28 | Reiterato | Laidlaw | Buy |
| 2017-03-10 | Reiterato | Laidlaw | Buy |
| 2016-10-13 | Iniziato | H.C. Wainwright | Buy |
| 2016-08-08 | Reiterato | Needham | Buy |
Mostra tutto
Cara Therapeutics Inc Borsa (CARA) Ultime notizie
Cara Therapeutics (NASDAQ:CARA) Coverage Initiated at StockNews.com - Defense World
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates ML, PWOD, NURO, CARA on Behalf of Shareholders - The Malaysian Reserve
CARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cara Therapeutics, Inc.CARA - Business Wire
Cara Therapeutics Files Certificate of Amendment for Reverse Stock Split and Shares Reduction - Defense World
Cara Therapeutics, Inc. Announces Appointment of Joseph Stauffer as Chief Medical Officer - Marketscreener.com
Cara Therapeutics, Inc. Announces Outcome from Dose- Finding Part A of the KIND 1 Study Evaluating Oral Difelikefalin for Mod Moderate-To-Severe Pruritus in Patients with Atopic Dermatitis - Marketscreener.com
Cara Therapeutics discontinues neurological condition study as drug fails - Marketscreener.com
Cara: Q2 Earnings Snapshot - Marketscreener.com
Cara Therapeutics stock hits 52-week high at $4.26 By Investing.com - Investing.com Nigeria
Cara shares jump 32% following reverse stock split - MSN
Cara Therapeutics Shares Rise 20% Following Reverse Stock Split - MarketWatch
Stock market news: Coeptis Therapeutics Holdings -96.03%, OptiNose -93.07% among biggest losers during mid day trading - Business Upturn
Stock market news: Coeptis Therapeutics Holdings declined by 96.03% whereas Baird Medical Investment Holdings +496.89% during mid day trading - Business Upturn
Stock market today: Coeptis Therapeutics Holdings -95.79%, OptiNose -93.64% among biggest losers in early trading - Business Upturn
Stock market today: Coeptis Therapeutics Holdings plunged by 95.98% whereas Baird Medical Investment Holdings gained over 201.90% in early trading - Business Upturn
Cara Therapeutics stock hits 52-week high at $4.26 - Investing.com India
Cara Therapeutics announces effective date for 1-for-12 reverse stock split - Hartford Business Journal
Cara Therapeutics, Inc. (NASDAQ:CARA) Given Average Rating of “Hold” by Brokerages - Defense World
Cara Therapeutics announces 1-for-12 reverse stock split to regain Nasdaq compliance - MSN
Cara Therapeutics to Implement 1-for-12 Reverse Stock Split - Marketscreener.com
Cara Therapeutics enacts reverse stock split - Investing.com
Cara Therapeutics Announces Effective Date of 1-for-12 Reverse Stock Split - The Manila Times
Cara Therapeutics (CARA) Announces 1-for-12 Reverse Stock Split to Maintain Nasdaq Listing - StockTitan
Cara Therapeutics, Inc. (NASDAQ:CARA) Shares Bought by Fmr LLC - Defense World
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PDCO, NURO, PWOD, CARA on Behalf of Shareholders - The Eastern Progress Online
StockNews.com Initiates Coverage on Cara Therapeutics (NASDAQ:CARA) - Defense World
Cara Therapeutics Enters Agreement to Merge with Tvardi Therapeutics - Defense World
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NURO, CARA, ARCH on Behalf of Shareholders - GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NURO, CARA, ZUO, BMTX on Behalf of Shareholders - The Malaysian Reserve
Cara in all-stock merger deal with Tvardi - MSN
Tvardi Therapeutics to go public in reverse merger with Connecticut company - The Business Journals
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Cara Therapeutics, Inc.CARA - The Eastern Progress Online
Cara Therapeutics accepts buyout from Houston's Tvardi Therapeutics, ending 20-year run in Connecticut - New Canaan Advertiser
Stamford’s Cara Therapeutics to merge with Houston biopharma firm - Hartford Business Journal
CARA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Cara Therapeutics, Inc. Is Fair to Shareholders - Business Wire
Cara Therapeutics and Tvardi Therapeutics To Merge - citybiz
Cara stock in focus after Tvardi merger deal (CARA:NASDAQ) - Seeking Alpha
Shareholder Alert: Ademi LLP Investigates Whether Cara Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders - The Bakersfield Californian
Cara Therapeutics to merge with Tvardi Therapeutics - Investing.com
Cara Therapeutics Subsidiary to Merge with Tvardi Therapeutics in All-Stock Deal - MarketWatch
Cara Therapeutics stock hits 52-week low at $0.24 amid market challenges By Investing.com - Investing.com South Africa
BNP Paribas Financial Markets Has $179,000 Stock Holdings in Cara Therapeutics, Inc. (NASDAQ:CARA) - Defense World
Cara Therapeutics stock hits 52-week low at $0.24 amid market challenges - Investing.com
Cara Therapeutics (NASDAQ:CARA) Now Covered by Analysts at StockNews.com - Defense World
Cara Therapeutics, Inc. (NASDAQ:CARA) Given Average Recommendation of “Hold” by Analysts - Defense World
Cara Therapeutics' SWOT analysis: stock's future hinges on oral DFK success - Investing.com
Cara Therapeutics Inc Azioni (CARA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.08%
0.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):